Inhalon Biopharma

Inhalon Biopharma’s platform enables inhaled antibodies to trap viruses and other pathogens in airway mucus, block their spread within the lung and clear them through natural mucus clearance.

Inhalon Biopharma announced an agreement with the University of Georgia to license a panel of human metapneumovirus antibodies, with plans to select candidates for clinical development.

Inhalon Biopharma planned presentations at Bio Investor Forum and Bio Europe. President and Chief Executive Officer John Whelan was to discuss progress in developing the company’s inhaled antibody platform.

Company selected to deliver oral presentation and poster showcasing preclinical data for first-in-class inhaled monoclonal antibody platform against RSV

Inhalon Biopharma announced initial Phase 1b results comparing the distribution and retention of antibodies in the human respiratory tract after inhaled and intravenous delivery.

Inhalon develops immunotherapies targeting viruses that are not treatable today and seeks candidates for research and development roles.

The Senior Director, Development role is responsible for leading Inhalon’s research and preclinical development programs for inhaled and prophylactic immunotherapies for acute respiratory infections.

Inhalon’s Vice President of Operations oversees operations, program execution, facilities and site-level functions at its Morrisville site.

President, Chief Executive Officer and Director

Richard Fuller provides clinical development and strategy advisory services to life science companies. He was a Research Fellow at Imperial College London, held clinical research executive roles at Glaxo Smith Kline, and directed Science Funding for the Wellcome Trust.

Richard Goozh founded Cambrian Growth Partners, a private investment and advisory firm focused on high-growth life sciences and high-tech companies. His career includes investment banking and Fortune 500 leadership roles.

Seth Hetherington, M.D., is a clinical development consultant to biotech companies and has published in medical and scientific literature. He earned his B.S. at Yale University and his M.D. at the University of North Carolina, Chapel Hill.

Inhalon Biopharma is a clinical-stage biotechnology company developing inhaled antibody treatments for acute respiratory infections.

Inhalon Biopharma is a clinical-stage biotechnology company with a precedent-setting inhaled drug platform for treating patients suffering from acute respiratory infections.

Inhalon Biopharma, Inc. is the sole administrator of the Inhalon website and has a registered office in County Westmeath, Ireland. The text identifies CLIENT as the data controller for personal data collected and processed when visitors use the website.